C4 Therapeutics, Inc. (CCCC) Financials
CCCC Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 376.5 million | 130.3 million |
2023-09-30 | 333.0 million | 117.0 million |
2023-06-30 | 375.0 million | 141.3 million |
2023-03-31 | 396.0 million | 133.6 million |
CCCC Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -24.2 million | 6.4 million |
2023-09-30 | -31.3 million | 8.2 million |
2023-06-30 | -19.4 million | 6.4 million |
2023-03-31 | -33.7 million | 6.3 million |
CCCC Net Income
No data available :(
CCCC Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 253.7 million | - | 71.0 million |
2023-09-30 | 216.6 million | - | 72.2 million |
2023-06-30 | 286.7 million | - | 73.4 million |
2023-03-31 | 305.0 million | - | 74.5 million |
CCCC Shares Outstanding
CCCC Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 157000 | 30.4 million | 10.3 million | 1.7 million |
2023-09-30 | 600000 | 28.3 million | 10.5 million | - |
2023-06-30 | 362000 | 29.9 million | 10.3 million | - |
2023-03-31 | 589000 | 29.0 million | 10.9 million | - |
CCCC Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 3.3 million | 1.7 million |
2023-09-30 | 11.1 million | 2.0 million |
2023-06-30 | 2.7 million | 2.0 million |
2023-03-31 | 3.8 million | 2.1 million |
CCCC
Price: $6.61
52 week price:
Earnings Per Share: -2.67 USD
P/E Ratio: -1.95
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 914600
Market Capitalization: 515.9 million